Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Operating lease liability | (549) | (171) |
| Net cash used in operating activities | (38,026) | (35,895) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | — | (21) |
| Net cash used in investing activities | — | (21) |
| Cash flows from financing activities | ||
| Proceeds from the issuance of debt | 74,992 | 99,965 |
| Payment of fees associated with debt | — | (125) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s capex?
- Inhibrx Biosciences, Inc. (INBX) reported capex of $0 in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s capex changed year-over-year?
- Inhibrx Biosciences, Inc.'s capex decreased by 100.0% year-over-year, from $21K to $0.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Inhibrx Biosciences, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude